Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts

Saturday, July 5, 2014

Acquired Diseases that Replicate the Defect of Genetic Diseases

In June, 2014, my book, entitled Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases was published by Elsevier. The book builds the argument that our best chance of curing the common diseases will come from studying and curing the rare diseases.



Phenocopy diseases are medical conditions that closely mimic a genetic disease, but are caused or triggered by an environmental factor. In many cases, phenocopy diseases are non-hereditary and acute. In some cases, the phenocopy disease is reversible when the environmental trigger is removed or when an appropriate treatment is applied.

Here is just one example of phenocopy disease (from my book):

Acquired conduction defect [the phenocopy disease] and inherited conduction defect [the rare, genetic disease that is copied by the phenocopy disease]
Disorders of the electrical systems in humans that defects of ion flux across membranes are known as channelopathies. The inherited cardiac conduction channelopathies were discussed in Section 5.3.

Because the anti-arrhythmogenic and anti-epileptic drugs typically target ion channels, they are the drugs most likely to produce, as an adverse side effect, disorders of cardiac conduction. For example, rufinamide, an oral antiepileptic drug, has been reported to cause QT-interval shortening [44]. Quinidine, disopyramide, and procainamide have been reported to produce QT prolongation [45].

Several channelopathies can be acquired as autoimmune diseases, in which antibodies react with ion channels, or related cellular components upon which the ion channels depend (e.g., myasthenia gravis, Lambert–Eaton myasthenic syndrome, cerebellar ataxia associated with VGCC antibodies, acquired neuromyotonia, Morvan fibrillary chorea, limbic encephalitis) [46].

Progressive familial heart block type IA is a genetic disorder of the cardiac conduction system. Clinically similar conditions can be acquired when the tissues of the conduction systems are damaged, as in: myocardial infarct, conduction system ischemia (i.e., lack of blood flow to components of the conduction system, particularly the His–Purkinje conduction tissue), age-related degeneration of conduction system, and complications of procedures (i.e., insertion of wires or lines into the heart chambers) [47].
In a similar fashion, there are some types of cancer that can have a genetic cause or an environmental cause (or both). For example, most lung cancer occurring in humans has an an acquired, environmental cause (i.e., smoking). Some cases of lung cancers are genetic (i.e., inherited NUT gene mutation in midline lung carcinoma of the young). The importance of the phenocopy diseases (acquired near-equivalents of rare genetic diseases) to our general understanding of cancer, and to the successful treatment of rare cancers and common cancers, is discussed in my book.

I urge you to read more about this book. There's a good preview of the book at the Google Books site. If you like the book, please request your librarian to purchase a copy of this book for your library or reading room.

- Jules J. Berman, Ph.D., M.D. tags: rare disease, common disease, orphan disease, orphan drugs, phenocopy disease, complex disease, heart block, arrhythmia, disease biology, cancer, carcinogenesis, acquired cancer, environmental cancer, rare cancer, common cancer

Friday, July 4, 2014

Aging and Cancer: Two Diseases of Cellular Renewal

In June, 2014, my book, entitled Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases was published by Elsevier. The book builds the argument that our best chance of curing the common diseases will come from studying and curing the rare diseases.



Chapter 4 explains that much what we think we know about the aging process comes from studying rare diseases of premature aging, such as Hutchinson–Gilford progeria syndrome, Bloom syndrome, Werner syndrome, Cockayne syndrome, dyskeratosis congenita, Fanconi anemia, Wolfram syndrome, and xeroderma pigmentosum. Lessons learned from these rare diseases are summarized in Chapter 4.

From Chapter 4:
4.4.3 Rule—On a cellular basis, aging is a process confined to non-renewable cell populations. Brief Rationale—Long-lived cells that cannot replace themselves, such as fully differentiated neurons, muscle cells, and cartilage cells, have no biological destiny other than degeneration and death.
As non-dividing cells undergo wear and tear, or suffer damage that cannot be repaired, they will die. The tissues in which these damaged cells reside will function with diminished capacity. For example, osteoarthritis is a chronic disease that occurs from repeated episodes of bone crunching on its cartilage cushion within joints. Osteoarthritis occurs primarily in weight-bearing joints, such as knees and hips. Over a lifetime, the cartilage is frayed and eroded. Injured chondrocytes do not divide, or they divide with insufficient zest to restore a normal cartilaginous cushion. As erosion of the cartilaginous lining continues, an inflammatory reaction develops in the joint. The inflammatory reaction produces pain, swelling, and associated clinical symptoms.

Consider oocytes. All of the oocytes that a woman will produce are present in utero, reaching a peak of about 7 million cells at 5 months’ gestation. After the peak is reached, about 3 months before birth, the oocytes begin to die; they are not replaced. The number of live oocytes declines until the number falls below a threshold of 1000, triggering menopause [28]. In this instance, as in every other example of human tissues undergoing aging, the process involves cells that cannot regenerate.

Frailty is a universal feature of old age. After the age of about 50, muscle mass gradually declines. The frailty associated with extreme aging is due, in part, to progressive sarcopenia. Muscle cells atrophy (i.e., reduce their size), die, and are not renewed. Frailty occurs because muscle cells were not designed to renew themselves continuously and indefinitely.

It was once thought that the brain cells you were born with are the same cells that you will die with; that brain cells do not divide. It is now known that regeneration (i.e., the growth of new neurons) occurs throughout life. This may be so, but new growth comes from reserve cells, not from fully differentiated neurons. Cell division cannot occur in a cell that becomes very large, like a neuron, and has appendages (i.e., an axon and dendrites) extending to and from other cells, sometimes over great distances (up to several feet in the case of motor neurons innervating foot muscles). Axons are ensheathed by a dependent network of periaxonal cells (i.e., oligodendrocytes in the central nervous system and Schwann cells in the peripheral nervous system). Neurons are transfixed anatomically, and cannot round up to divide. Hence, the fully mature neuron has little or no regenerative opportunity. Consequently, many of the cellular changes that we associate with aging take place in neurons. The dementia that accompanies aging is due to the inability of injured neurons to repair or replace

The tauopathies are disorders wherein tau protein accumulates within neurons. Tau proteins are involved in the stabilization of microtubules in every cell throughout the body, but they accumulate to the greatest extent in the neurons of the central nervous system. If a fully differentiated neuron cannot clear its tau proteins, it will suffer progressive damage, leading to cell death. Though tau proteins are ubiquitous, the tauopathies always develop as neurodegenerative disorders. Examples of diseases in which tau proteins are found include: Alzheimer’s disease, progressive supranuclear palsy, argyrophilic grain disease, corticobasal degeneration, dementia pugilistica, a form of Parkinsonism known as Lytico–Bodig disease or as Parkinson–dementia complex of Guam, a form of Parkinsonism linked to chromosome 17, frontotemporal dementia, frontotemporal lobar degeneration, Hallervorden–Spatz disease, lipofuscinosis, meningioangiomatosis, Pick’s disease, a rare tumor of neurons known as ganglioglioma [29], subacute sclerosing panencephalitis, lead encephalopathy, tangle-predominant dementia, and tuberous sclerosis.

Agin The prion diseases are another example of disorders that target non-dividing neurons. The term prion was introduced in 1982 by Stanley Prusiner [30]. Prions are the only infectious agent that contains neither DNA nor RNA. A prion is a misfolded protein that can serve as a template for proteins of the same type to misfold, producing globs of non-functioning protein, causing cells to degenerate. The site of greatest accumulation of prion protein is in brain cells. Though few scientists would consider prions to be organisms, living or otherwise, they are undoubtedly transmissible infectious agents. The most common mode of transmission of prion disease is through the consumption of brains of infected animals.

The cells of the body that are most vulnerable to prion disease are the neurons of the brain. The reason for the particular sensitivity of neurons to prion disease relates to the limited ability of neurons to replicate (i.e., to replace damaged neurons with new neurons), reconnect (to replace damaged connections between a neuron and other cells), and to remove degenerated cells and debris. There are five known prion diseases of humans, and all of them produce encephalopathies characterized by decreasing cognitive ability and impaired motor coordination. They are: Kuru, Creutzfeldt–Jakob disease, bovine spongiform encephalopathy (known in humans as new variant Creutzfeldt–Jakob disease), Gerstmann–Straussler–Scheinker syndrome, and fatal familial insomnia. At present, all of the prion diseases are progressive and fatal. Prions have been observed in fungi, where their accumulation does not seem to produce any deleterious effect, and may even be advantageous to the organism [31].

In Section 4.3, we listed the many causative mechanisms underlying the rare diseases of premature aging. Without exception, every disease of premature aging creates a defect in the normal process of cellular renewal. If we understood how to control and maintain stem cell renewal, a feat that nematodes seem to have mastered, then we might understand how to defeat the aging process. In Chapter 7, we will be discussing cancer, another disorder of cell renewal. Whereas aging is a disease of cells that cannot divide, cancer is a disease of cells that cannot stop dividing.
I urge you to read more about this book. There's a good preview of the book at the Google Books site. If you like the book, please request your librarian to purchase a copy of this book for your library or reading room.

- Jules J. Berman, Ph.D., M.D. tags: carcinogenesis, cancer and aging, rare disease, common disease, aging, ageing, cell renewal, cancer, cause of aging, biology of aging, orphan disease, orphan drugs

Wednesday, July 2, 2014

Cancer and Aging are Both Diseases of Cellular Renewal

In June, 2014, my book, entitled Rare Diseases and Orphan Drugs: Keys to Understanding and Treating the Common Diseases was published by Elsevier. The book builds the argument that our best chance of curing the common diseases will come from studying and curing the rare diseases.



There is a relationship between aging and cancer. Whereas aging is a disease of cells that cannot divide, cancer is a disease of cells that cannot stop dividing. Both diseases involve the processes of cellular renewal. If we understood aging, we would probably understand cancer.

Chapter 4 tackles the subject of human aging. Much of what we know about the aging process comes from studying rare diseases of premature aging, such as Hutchinson–Gilford progeria syndrome, Bloom syndrome, Werner syndrome, Cockayne syndrome, dyskeratosis congenita, Fanconi anemia, Wolfram syndrome, and xeroderma pigmentosum. The relationship between a these premature aging syndromes and natural aging processes are discussed in Chapter 4. The chapter synthesizes an approach to understanding aging gained by understanding the biological pathways that lead to cell death and degeneration in non-dividing cell populations.

Here is an excerpt from Chapter 4,
4.1.1 Rule—We do not have a scientifically meaningful definition for the diseases of aging. Brief Rationale—We do not know the cellular basis of aging; hence, we cannot determine whether a disease qualifies as a disease of aging on a cellular basis.
The majority of the so-called diseases of aging are conditions that make individuals look like old persons, or they are conditions that happen to occur more often in elderly individuals than in young individuals. One of the few points that experts in the field of aging can agree on is that the aging process is complex; not caused by any single factor.
4.1.2 Rule—Aging is not caused by a single gene. Brief Rationale—If aging were caused by a single gene, you would expect rare occurrences of loss-of-function mutations of the gene, leading to instances of human immortality. Outside of science fiction, immortal humans do not exist.
Most of us gauge aging by looking for visible features that always seem to be present in older individuals, and that are absent in youth. For the most part, these signs have very little to do with the biological aging process. The most familiar example is wrinkling and sagging. Wrinkling is a condition producedby chronic exposure to ultraviolet (UV) light. Over time, UV light denatures the connective tissue in the dermis, producing a condition called senile elastosis or, more accurately, solar elastosis. Most of the skin changes associated with aging, such as cracking, leathery texture, and poor elasticity (i.e., the ability of skin to regain its flat, tight surface after being stretched or pinched), are the result of chronic UV toxicity.

The other obvious change observed in older individuals is skin sagging. In many individuals, this is most pronounced in the folds of skin that grow under the chin and down the neck. Sagging flesh on older individuals is due entirely to two phenomena. The first is skin growth; humans grow their skin throughout life. This skin accumulates to different degrees in different individuals, depending on their genetically determined propensities for skin growth.

The other phenomenon is gravity. Without the effects of gravity, our skin would grow evenly over our body contours. We develop pendulous skin at sites with the least skeletal support (e.g., under chin, under breasts, under our arms). The changes we see in the skin of older individuals are due to the chronic effects of UV light, skin growth throughout life, and gravity that occur over time. They are not fundamental features of biological aging, because they do not occur in the absence of toxic conditions.

Is there any evidence to support this claim? One piece of evidence lies in differences in skin damage among races. The heavily pigmented races have much less wrinkling than the less pigmented races, because they are better shielded from UV light. Yet there is no corresponding extension of life expectancy among the less-wrinkled races, suggesting that damaged skin is unrelated to the aging process. Aside from that, any elderly person can do a simple experiment that will doubtless settle the issue for them. Strip off your clothes and inspect the parts of your body that are not exposed to light and that are not hanging from an anatomic prominence. For some, this would be the lower back or the upper thigh. In almost every case, you will be gratified to learn that this region of skin is unwrinkled, youthfully elastotic (i.e., will snap back in place when pinched), and relatively flat. Aside from a bit of softness due to skin growth, there really is not much difference between these protected regions of skin in elderly individuals and in young individuals. At this point, you can put your clothes back on, if you wish.

If wrinkling and sagging are not part of the aging process, then what physiological processes characterize aging?
As with every common disease, the biological basis of human aging is best understood by examining rare diseases that involve the aging process.

I urge you to read more about this book. There's a good preview of the book at the Google Books site. If you like the book, please request your librarian to purchase a copy of this book for your library or reading room.

- Jules J. Berman, Ph.D., M.D. tags: rare disease, common disease, cancer, aging, orphan disease, orphan drugs, cellular renewal, post-mitotic cell, wrinkling, sagging, uv light

Monday, October 11, 2010

Overview of neoplastic development

Modern tumor biology is pre-occupied with oncogenes and tumor suppressors. For the past several decades, cancer researchers have attemptedt o understand how specific genetic alterations contribute to the malignant phenotype. Certainly, research in tumor genetics has led to great advances in our understanding of cancer.

Still, tumor genetics has not really helped us understand tumor speciation. Tumor speciation is an area that gets very little attention from most cancer researchers, but if you don't have a grip on the general phenomenon of tumor speciation, you're not going to fully understand tumor classification, or carcinogenesis (the necessary biological steps leading to the development of cancer), or the biology of precancers (lesions that precede the development of cancer), or the class-based approach to precancer treatment.

Much of my book Neoplasms: Principles of Development and Diversity, is devoted to the subjects of tumor speciation and classification. I've also written about the phenomenon in prior blogs. Here's a discussion of tumor speciation, condensed to a few paragraphs.

Tumor genetics tells us that most of the common cancers occurring in adult humans are genetically complex, with thousands of mutations in tumor cells, and enormous genetic heterogeneity among the different cancer cells within the same tumor. Just as every human is genetically unique, so is every cancer that has ever occurred. If this is the case, why are the different types of cancers restricted to just a few hundred species of tumors (e.g., Wilms' tumor, chronic myelogenous leukemia, pheochromocytoma, hepatocellular carcinoma, malignant melanoma). The individual specimens within each tumor species look about the same under a microscope (that's how we diagnose them) and behave within somewhat predictable biologic paramaters. If cancers are genetically diverse, and if genetics is responsible for the behavior of cancers, wouldn't you expect to find a near-infinite number of tumor species?

The hypothesis developed in my book is that while cancer is caused by genes, tumors are speciated by epigenes, the non-sequence DNA changes that determine cellular differentiation in normal cells. Just as normal cells of the human body are restricted to a few hundred differentiated cell types [by the epigenome], cancer cells are restricted to a finite number of cell types [by the epigenome].

During carcinogeneis, cumulative genetic changes occur, but these changes must somehow fit into an epigenomic pattern that supports the continued growth of the tumor. In short, carcinogenesis is a genetic phenomenon, but tumor speciation is an epigenetic phenomenon.

Precancers are a late-stage epigenomic adjustment. If the adjustment is successful, from the perspective of the cancer cell, the precancer can develop into a cancer of a specific tumor species. Otherwise, the precancer regresses [spontaneously dies]. Precancers can be thought of as biological experiments conducted by cells undergoing carcinogenesis. Sometimes the experiment fails (and the precancer regresses). You're never sure of the result of the experiment (i.e., a precancer may develop into any one of several different tumor species, as in the case of bronchogenic precancers).

I admit that this all seems vague, but that's what happens when you try to cover a complex subject in a few paragraphs, without the aid of examples.

In the next blog, I'll introduce malignant rhabdoid tumors, and I'll try to explain how this unique tumor provides perspective to the whole problem of speciation.

Jump to tomorrow's post
Visit yesterday's post

-© 2010 Jules J. Berman

key words: cancer, neoplasia, neoplasms, precancer, tumor biology, tumour biology, carcinogenesis, cancer development, pre-cancer, precancerous lesions, pre-malignant lesions, neoplastic development

Sunday, October 10, 2010

Neoplasms: new blog site

This is the first blog of my third blog site. My other two blog sites are: Specified Life and Machiavelli's Laboratory . The Specified Life blog deals with information retrieval, organization, indexing, annotation, classification and analysis. Machiavelli's Laboratory is a blog devoted to issues covered in my satiric online book, Machiavelli's Laboratory, a free ebook on scientific ethics, explained from the perspective of an unethical scientist.

I've written two books about cancer: Neoplasms: Principles of Development and Diversity, and Precancer: The Beginning and the End of Cancer.

My philosophy, in a nutshell, is this: Malignant cancers are very hard to treat, but they are preceded by precancers, that are much easier to treat. If we successfully treated all of the precancers, we would stop all new cancers from developing. Though there are many different neoplasms (i.e., cancers and precancers), we can classify neoplasms into groups with shared properties. These shared properties can be exploited to develop effective treatments that target all of the members of the same class. By dividing neoplasms into sensible classes, and by developing targeted treatments for the precancers within each class, we can put an end to human cancer.

There are many important cancer topics that could not be fully explored in my two published cancer books. I've been writing about cancer in my Specified Life blog, but it makes a poor fit. It's probably best to have a dedicated blog site written for cancer reserachers, pathologists, and healthcare professionals who might be interested in my approach to neoplasia.

In the next few weeks, I plan to expand my discussion of germ cell tumors, started in the Specified Life blog, and to begin a series on epigenomic neoplasia; malignant rhabdoid tumor serving as the prototype.

Jump to tomorrow's blog

-© 2010 Jules J. Berman

key words: cancer, neoplasia, neoplasms, precancer, tumor biology, tumour biology, carcinogenesis, cancer development, pre-cancer, precancerous lesions, pre-malignant lesions, neoplastic development